RESUMO
Dihydroartemisinin-piperaquine, which was registered in 2017 in Senegal, is not currently used as the first-line treatment against uncomplicated malaria. A total of 6.6% to 17.1% of P. falciparum isolates collected in Dakar in 2013 to 2015 showed ex vivo-reduced susceptibility to piperaquine. Neither the exonuclease E415G mutation nor the copy number variation of the plasmepsin II gene (Pfpm2), associated with piperaquine resistance in Cambodia, was detected in Senegalese parasites.
Assuntos
Artemisininas/uso terapêutico , Ácido Aspártico Endopeptidases/uso terapêutico , Plasmodium falciparum/efeitos dos fármacos , Proteínas de Protozoários/uso terapêutico , Quinolinas/uso terapêutico , Animais , Antimaláricos/uso terapêutico , Variações do Número de Cópias de DNA , Humanos , Malária Falciparum/tratamento farmacológico , Senegal , Falha de TratamentoRESUMO
Polymorphisms and the overexpression of transporter genes, especially of the ATP-binding cassette superfamily, have been involved in antimalarial drug resistance. The objective of this study was to use 77 Senegalese Plasmodium falciparum isolates to evaluate the association between the number of Asn residues in the polymorphic microsatellite region of the Plasmodium falciparum multidrug resistance 6 gene (Pfmdr6) and the ex vivo susceptibility to antimalarials. A significant association was observed between the presence of 7 or 9 Asn repeats and reduced susceptibility to quinine.
Assuntos
Transportadores de Cassetes de Ligação de ATP/genética , Antimaláricos/farmacologia , Resistência a Medicamentos/genética , Plasmodium falciparum/genética , Polimorfismo Genético , Proteínas de Protozoários/genética , Quinina/farmacologia , Amodiaquina/análogos & derivados , Amodiaquina/farmacologia , Artemisininas/farmacologia , Artesunato , Asparagina/metabolismo , Cloroquina/farmacologia , Doxiciclina/farmacologia , Etanolaminas/farmacologia , Fluorenos/farmacologia , Expressão Gênica , Humanos , Concentração Inibidora 50 , Lumefantrina , Malária Falciparum/parasitologia , Mefloquina/farmacologia , Naftiridinas/farmacologia , Plasmodium falciparum/efeitos dos fármacos , Plasmodium falciparum/crescimento & desenvolvimento , Plasmodium falciparum/isolamento & purificação , Isoformas de Proteínas/genética , Quinolinas/farmacologia , Sequências Repetitivas de Aminoácidos , SenegalRESUMO
BACKGROUND: In response to increasing resistance to anti-malarial drugs, Senegal adopted artemisinin-based combination therapy (ACT) as the first-line treatment for uncomplicated malaria in 2006. However, resistance of Plasmodium falciparum parasites to artemisinin derivatives, characterized by delayed parasite clearance after treatment with ACT or artesunate monotherapy, has recently emerged and rapidly spread in Southeast Asia. After 10 years of stability with rates ranging from 5.6 to 11.8%, the prevalence of parasites with reduced susceptibility in vitro to monodesethylamodiaquine, the active metabolite of an ACT partner drug, increased to 30.6% in 2014 in Dakar. Additionally, after a decrease of the in vitro chloroquine resistance in Dakar in 2009-2011, the prevalence of parasites that showed in vitro chloroquine resistance increased again to approximately 50% in Dakar since 2013. The aim of this study was to follow the evolution of the susceptibility to ACT partners and other anti-malarial drugs in 2015 in Dakar. An in vitro test is the only method currently available to provide an early indication of resistance to ACT partners. RESULTS: Thirty-two P. falciparum isolates collected in 2015 in Dakar were analysed using a standard ex vivo assay based on an HRP2 ELISA. The prevalence of P. falciparum parasites with reduced susceptibility in vitro to monodesethylamodiaquine, chloroquine, mefloquine, doxycycline and quinine was 28.1, 46.9, 45.2, 31.2 and 9.7%, respectively. None of the parasites were resistant to lumefantrine, piperaquine, pyronaridine, dihydroartemisinin and artesunate. These results confirm an increase in the reduced susceptibility to monodesethylamodiaquine observed in 2014 in Dakar and the chloroquine resistance observed in 2013. The in vitro resistance seems to be established in Dakar. Additionally, the prevalence of parasites with reduced susceptibility to doxycycline has increased two-fold compared to 2014. CONCLUSIONS: The establishment of a reduced susceptibility to monodesethylamodiaquine as well as chloroquine resistance, and the emergence of a reduced susceptibility to doxycycline are disturbing. The in vitro and in vivo surveillance of anti-malarial drugs must be implemented in Senegal.
Assuntos
Amodiaquina/análogos & derivados , Antimaláricos/farmacologia , Cloroquina/farmacologia , Resistência a Medicamentos , Plasmodium falciparum/efeitos dos fármacos , Amodiaquina/farmacologia , Artemisininas/farmacologia , Quimioterapia Combinada , SenegalRESUMO
The RING E3 ubiquitin protein ligase is crucial for facilitating the transfer of ubiquitin. The only polymorphism identified in the E3 ubiquitin protein ligase gene was the D113N mutation (62.5%) but was not significantly associated with the 50% inhibitory concentration (IC50) of conventional antimalarial drugs. However, some mutated isolates (D113N) present a trend of reduced susceptibility to piperaquine (P = 0.0938). To evaluate the association of D113N polymorphism with susceptibility to antimalarials, more isolates are necessary.
Assuntos
Antimaláricos/farmacologia , Plasmodium falciparum/efeitos dos fármacos , Plasmodium falciparum/genética , Polimorfismo Genético/genética , Ubiquitina-Proteína Ligases/genética , Artemisininas/farmacologia , Artesunato , Cloroquina/análogos & derivados , Cloroquina/farmacologia , Doxiciclina/farmacologia , Etanolaminas/farmacologia , Fluorenos/farmacologia , Lumefantrina , Mefloquina/farmacologia , Naftiridinas/farmacologia , Quinina/farmacologia , Quinolinas/farmacologia , SenegalRESUMO
BACKGROUND: To determine the impact of the introduction of artemisinin-based combination therapy (ACT) on parasite susceptibility, a molecular surveillance for antimalarial drug resistance was conducted on local isolates from the Hôpital Principal de Dakar between November 2013 and January 2014 and between August 2014 and December 2014. METHODS: The prevalence of genetic polymorphisms in antimalarial resistance genes (pfcrt, pfmdr1, pfdhfr and pfdhps) was evaluated in 103 isolates. RESULTS: The chloroquine-resistant haplotypes CVIET and CVMET were identified in 31.4 and 3.9 % of the isolates, respectively. The frequency of the pfcrt K76T mutation was increased from 29.3 % in 2013-2014 to 43.2 % in 2014. The pfmdr1 N86Y and Y184F mutations were identified in 6.1 and 53.5 % of the isolates, respectively. The pfdhfr triple mutant (S108N, N51I and C59R) was detected in the majority of the isolates (82.3 %). The prevalence of quadruple mutants (pfdhfr S108N, N51I, C59R and pfdhps A437G) was 40.4 %. One isolate (1.1 %) harboured the pfdhps mutations A437G and K540E and the pfdhfr mutations S108N, N51I and C59R. CONCLUSIONS: Despite a decline in the prevalence of chloroquine resistance due to the official withdrawal of the drug and to the introduction of ACT, the spread of resistance to chloroquine has continued. Furthermore, susceptibility to amodiaquine may be decreased as a result of cross-resistance. The frequency of the pfmdr1 mutation N86Y declined while the Y184F mutation increased in prevalence, suggesting that selective pressure is acting on pfmdr1, leading to a high prevalence of mutations in these isolates and the lack of specific mutations. The 50.5 % prevalence of the pfmdr1 polymorphisms N86Y and Y184F suggests a decrease in lumefantrine susceptibility. Based on these results, intensive surveillance of ACT partner drugs must be conducted regularly in Senegal.
Assuntos
Antimaláricos/farmacologia , Resistência a Medicamentos , Genes de Protozoários , Plasmodium falciparum/efeitos dos fármacos , Plasmodium falciparum/genética , Substituição de Aminoácidos , Amodiaquina/farmacologia , Cloroquina/farmacologia , Humanos , Proteínas de Membrana Transportadoras/genética , Proteínas Associadas à Resistência a Múltiplos Medicamentos/genética , Peptídeo Sintases/genética , Plasmodium falciparum/isolamento & purificação , Polimorfismo Genético , Prevalência , Proteínas de Protozoários/genética , Senegal , Tetra-Hidrofolato Desidrogenase/genéticaRESUMO
OBJECTIVES: To analyze the main causes and risk factors of death in intensive care. PATIENTS AND METHOD: Prospective observational study in the intensive care units in Hospital Principal of Dakar from July to December 2018 including all patients who died 24 hours after admission. Demographic, clinical, severity (IGSII, APACHE II, MPM) and organ failure (SOFA, LODS) scores were collected. A multiparametric comparison was made between deceased and surviving patients. RESULTS: The overall mortality was 25.86% correlated with the probability of death (MPM): 26.4%. The mean age was 50.98 [8-94 years] with a sex ratio of 1.15. The majority of deaths (79.26%) occurred outside of duty hours and 70.7% had at least one medical history. The mean severity scores were for IGSII 40.12 +/- 17.25 and for APACHE II 18.31 +/- 8.49. The mean visceral failure scores were for SOFA 7.02 +/- 4.44 and for LODS 5.73 +/- 3.35. Complications were dominated by nosocomial infections (48.78%) and are responsible for 37.8% of deaths. The mean length of stay was 7.30 days +/- 7.46. Age, the existence of organ failure, the use of vasopressors, the occurrence of nosocomial infections and the absence of a senior doctor were correlated with mortality. CONCLUSION: The intensive care unit mortality rate is 25.86%. Advanced age, the existence of organ failures and the occurrence of a nosocomial infection are factors in the occurrence of death.
OBJECTIFS: Analyser les principales causes et les facteurs de risque de décès en réanimation. PATIENTS ET MÉTHODE: Etude prospective observationnelle dans les services de réanimation de l'hôpital Principal de Dakar de Juillet à Décembre 2018 incluant tous les patients décédés 24 heures après l'admission.Nous avonsétudiés, les données démographiques, cliniques, les scores de gravité (IGSII, APACHE II, MPM) et de défaillance d'organe (SOFA, LODS).Une comparaison multiparamétrique a été faite entre les patients décédés et survivants. RÉSULTATS: La mortalité globale était de 25,86% corrélée avec la probabilité de décès (MPM) de 26,4%. L'âge moyen était de 50,98 [8-94 ans] avec un sex-ratio H/F : 1,15. La majorité des décès (79,26%) était survenue durant la nuit, les week-end et jours fériés, l'activité étant assurée en ce moment par l'équipe de garde constituée de deux médecins en fin de spécialisation en anesthésie-réanimation et un médecin sénior d'astreinte pouvant être appelé en cas de nécessité. Des antécédents pathologiques avaient été retrouvés chez 70,7% des patients décédés.Le score de gravité IGSII était en moyenne de 40,12 +/- 17,25 et l'APACHE II de 18,31 +/- 8,49. Le score de défaillance viscérale moyen était pour le SOFA de 7,02 +/-4,44 et pour le LODS de 5,73+/-3,35. Les complications étaient dominées par les infections nosocomiales (48,78%) et sont associées à 37,8% des décès (p<0,0001 et OR [IC 95%] 22,8 [7,6-68,2]). La durée moyenne de séjour était de 7,30 jours +/-7,46. L'âge, la défaillance d'organe, l'utilisation de vasopresseurs, l'infection nosocomiale étaient corrélés à la mortalité. CONCLUSION: Le taux de mortalité en réanimation est de 25,86%. L'âge avancé, l'existence de défaillance d'organe et la survenue d'une infection nosocomiale sont des facteurs de survenue de décès.
RESUMO
The emergence of resistance to artemisinin-based combination therapies (ACT) was described in Southeast Asia. In this context, the identification of molecular markers of ACT resistance partner drugs is urgently needed for monitoring the emergence and spread of resistance. Polymorphisms in transporter genes, especially of the ATP-binding cassette (ABC) superfamily, have been involved in anti-malarial drug resistance. In this study, the association between the mutations in the P. falciparum multidrug resistance 1 gene (pfmdr1, N86Y, Y184 F, S1034C, N1042D and D1246Y) or repetitive amino acid motifs in pfmdr5 and the ex vivo susceptibility to anti-malarial drugs was evaluated. Susceptibility to chloroquine, quinine, monodesethylamodiaquine, lumefantrine, piperaquine, pyronaridine, mefloquine and dihydroartemisinin was assessed in 67 Senegalese isolates. The shorter DNNN motif ranged from to 2 to 11 copy repeats, and the longer DHHNDHNNDNNN motif ranged from 0 to 2 in pfmdr5. The present study showed the association between repetitive amino acid motifs (DNNN-DHHNDDHNNDNNN) in pfmdr5 and in vitro susceptibility to 4-aminoquinoline-based antimalarial drugs. The parasites with 8 and more copy repeats of DNNN in pfmdr5 were significantly more susceptible to piperaquine. There was a significant association between parasites whose DHHNDHNNDNNN motif was absent and replaced by DHHNDNNN, DHHNDHNNDHNNDNNN or DHHNDHNNDHNNDHNNDNNN and increased susceptibility to chloroquine, monodesethylamodiaquine and pyronaridine. A significant association between both the wild-type allele N86 in pfmdr1 and the N86-184 F haplotype and reduced susceptibility to lumefantrine was confirmed. Further studies with a large number of samples are required to validate the association between these pfmdr5 alleles and the modulation of 4-aminoquinoline-based antimalarial drug susceptibility.
Assuntos
Antimaláricos/farmacologia , Resistência a Medicamentos/genética , Proteínas Associadas à Resistência a Múltiplos Medicamentos/genética , Plasmodium falciparum/efeitos dos fármacos , Polimorfismo Genético , Proteínas de Protozoários/metabolismo , Transportadores de Cassetes de Ligação de ATP/metabolismo , Haplótipos , Humanos , Malária Falciparum/parasitologia , Proteínas de Membrana Transportadoras/genética , Plasmodium falciparum/genética , Proteínas de Protozoários/genéticaRESUMO
Resistance to most antimalarial drugs has spread from Southeast Asia to Africa. Accordingly, new therapies to use with artemisinin-based combination therapy (triple ACT) are urgently needed. Proveblue, a methylene blue preparation, was found to exhibit antimalarial activity against Plasmodium falciparum strains in vitro. Proveblue has synergistic effects when used in combination with dihydroartemisinin, and has been shown to significantly reduce or prevent cerebral malaria in mice. The objectives of the current study were to evaluate the in vitro baseline susceptibility of clinical field isolates to Proveblue, compare its activity with that of other standard antimalarial drugs and define the patterns of cross-susceptibility between Proveblue and conventional antimalarial drugs. The Proveblue IC50 of 76 P. falciparum isolates ranged from 0.5 nM to 135.1 nM, with a mean of 8.1 nM [95% confidence interval, 6.4-10.3]. Proveblue was found to be more active against P. falciparum parasites than chloroquine, quinine, monodesethylamodiaquine, mefloquine, piperaquine, doxycycline (P <0.001) and lumefantrine (P = 0.014). Proveblue was as active as pyronaridine (P = 0.927), but was less active than dihydroartemisinin and artesunate (P <0.001). The only significant cross-susceptibilities found were between Proveblue and dihydroartemisinin (r2 = 0.195, P = 0.0001), artesunate (r2 = 0.187, P = 0.0002) and piperaquine (r2 = 0.063, P = 0.029). The present study clearly demonstrates the potential of Proveblue as an effective therapeutic agent against P. falciparum. In this context, the use of Proveblue as part of the triple ACT treatment for multidrug-resistant malaria warrants further investigation.
Assuntos
Antimaláricos/farmacologia , Inibidores Enzimáticos/farmacologia , Azul de Metileno/farmacologia , Plasmodium falciparum/efeitos dos fármacos , Humanos , Concentração Inibidora 50 , Malária Falciparum/parasitologia , Testes de Sensibilidade Parasitária , Plasmodium falciparum/isolamento & purificação , SenegalRESUMO
In 2006, the Senegalese National Malaria Control Programme recommended artemisinin-based combination therapy as first-line treatment for uncomplicated malaria. In addition, intravenous (i.v.) injection of artesunate and artemether has gradually replaced quinine for the treatment of severe malaria. Mutations in the propeller domain of the Kelch 13 gene (K13-propeller, PF3D71343700), such as Y493H, R539T, I543T and C580Y, were recently associated with in vivo and in vitro resistance to artemisinin in Southeast Asia. However, these mutations were not identified in Africa. In total, 181 isolates of Plasmodium falciparum from 161 patients from Dakar, Senegal, were collected between August 2015 and January 2016. The K13-propeller gene of the isolates was sequenced. A search for non-synonymous mutations in the propeller region of K13 was performed in the 181 isolates collected from Dakar from 2015 to 2016. Three synonymous mutations were detected (D464D, C469C and R471R). Of 119 patients treated with i.v. artesunate or intramuscular artemether followed by artemether/lumefantrine, 9 patients were still parasitaemic on Day 3. Parasites from these nine patients were wild-type for K13-propeller. None of the polymorphisms known to be involved in artemisinin resistance in Asia were detected. These results suggest that K13 is not the best predictive marker for artemisinin resistance in Africa. More isolates from clinical failure cases or patients with delayed parasite clearance after treatment with artemisinin derivatives are necessary to identify new molecular markers.